We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
- Authors
Simoons, M L; GUSTO IV-ACS Investigators
- Abstract
Glycoprotein IIb/IIIa blockers reduce procedure-related thrombotic complications of percutaneous coronary intervention, and the risk of death and myocardial infarction in patients with acute coronary syndromes. The effect on risk of death and myocardial infarction is particularly apparent in patients undergoing early percutaneous coronary interventions. We did a randomised, multicentre trial to study the effect of the glycoprotein IIb/IIIa blocker abciximab on patients with acute coronary syndromes who were not undergoing early revascularisation.
- Publication
Lancet (London, England), 2001, Vol 357, Issue 9272, p1915
- ISSN
0140-6736
- Publication type
Journal Article
- DOI
10.1016/s0140-6736(00)05060-1